Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Soars on New CEO News


The institutional investor held 715,483 shares of the transportation company at the end of 2016Q4, valued at $61.03 million, down from 721,988 at the end of the previous reported quarter. Cliftonlarsonallen Wealth Advisors Llc who had been investing in Us Bancorp Del for a number of months, seems to be less bullish one the $83.61B market cap company. Kistler Tiffany Companies LLC now owns 3,673 shares of the company's stock worth $122,000 after acquiring an additional 1,571 shares in the last quarter. AeroGrow International, Inc. (OTCMKTS:AERO) has 0.00% since September 11, 2016 and is. It has outperformed by 7.96% the S&P500.

Rhenman & Partners Asset Management Ab, which manages about $521.63M US Long portfolio, decreased its stake in Biogen Inc (NASDAQ:BIIB) by 21,000 shares to 36,000 shares, valued at $10.21M in 2016Q4, according to the filing.

Among 28 analysts covering Teva Pharma (NYSE:TEVA), 6 have Buy rating, 4 Sell and 18 Hold. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%.

"Schultz will be Teva's fourth CEO over the last six years, and we think Teva must stabilize its executive ranks to execute on its turnaround strategy and lower its high debt level, now at $34 billion", said analyst Jeffrey Loo, with CFRA Research, in a client note. Teva Pharmaceutical Industries Limited presently has an average rating of "Hold" and a consensus price target of $34.50.

In July, news reports circulated that Teva was going to offer the top job to AstraZeneca CEO Pascal Soriot. Credit Suisse downgraded Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Tuesday, September 5 to "Sell" rating. The third largest holder is Fmr Llc, which now holds $662.81 million worth of this stock and that ownership represents almost 4.28% of its market capitalization. The rating was maintained by RBC Capital Markets with "Outperform" on Wednesday, November 16. Maxim Group reiterated a "hold" rating and issued a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, July 13th. The firm has "Neutral" rating by Citigroup given on Wednesday, August 16.

Teva announced today that it has hired Kare Schultz as its new president and CEO.

"Republican efforts around repeal and replace and potential impacts on utilization, public consternation around drug prices increases, and further pressure on drug pricing in generics from more powerful payor groups all created too much of a cloud of uncertainty to recommend an overweight position on the sector as a whole despite compelling relative valuation", analysts at brokerage Morgan Stanley said in a research note.

Since May 3, 2017, it had 0 buys, and 3 selling transactions for $2.29 million activity.

Investors sentiment is 2.5 in Q4 2016. Its down 0.03, from 1.05 in 2016Q3.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Riverbridge Prtnrs Ltd Liability Corp has 0.05% invested in U.S. Bancorp (NYSE:USB) for 46,539 shares. Cwm Lc stated it has 652 shares. Ftb Advsrs Incorporated invested 0% of its portfolio in Wendys Co (NASDAQ:WEN). Buckhead Mngmt Ltd Com accumulated 1.88% or 193,080 shares. The Ohio-based Huntington National Bank has invested 0.01% in the stock.